Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|November 1, 1999
Supplements and Featured Publications
- The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
- Volume 5
- Issue 17 Suppl
Participating Faculty
Advertisement
Articles in this issue
almost 27 years ago
Introductionalmost 27 years ago
Epidemiology of Pneumococcal Diseasealmost 27 years ago
The Costs of Antimicrobial Treatment Failure in Acute Otitis Mediaalmost 27 years ago
Prevention of Pneumococcal Disease in High-Risk Pediatric Groupsalmost 27 years ago
The Clinical Impact of Pneumococcal Conjugate Vaccinesalmost 27 years ago
Economic Impact of Pneumococcal Conjugate Vaccine in Managed Carealmost 27 years ago
Into the Era of the Pneumococcal Conjugate Vaccinealmost 27 years ago
Selected Abstractsalmost 27 years ago
CME Quizalmost 27 years ago
BibliographyAdvertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
3
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
4
Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD
5